1. V. Forster, J.-C. Leroux, Nano-antidotes for drug overdose and poisoning. Sci. Transl. Med. 7(290), 290ps14–290psps14 (2015)
2. H. Hedegaard, M. Warner, A.M. Miniño, Drug overdose deaths in the United States, 1999–2015: US Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics (2017)
3. R.C. Dart, L.R. Goldfrank, B.L. Erstad, D.T. Huang, K.H. Todd, J. Weitz et al., Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care. Ann. Emerg. Med. 54(3), 386–394 (2017)
4. S. Glund, V. Moschetti, S. Norris, J. Stangier, M. Schmohl, J. van Ryn et al., A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb. Haemost. 114(05), 943–951 (2015)
5. V. Paget, J. Sergent, R. Grall, S. Altmeyer-Morel, H. Girard, T. Petit et al., Carboxylated nanodiamonds are neither cytotoxic nor genotoxic on liver, kidney, intestine and lung human cell lines. Nanotoxicology 8(sup1), 46–56 (2014)